Advyzon Investment Management LLC Makes New $561,000 Investment in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• Advyzon Investment Management LLC acquired 1,134 shares of Intuitive Surgical, Inc., valued at approximately $561,000, indicating growing institutional interest in the company.
• Analysts have issued varying ratings for Intuitive Surgical, with an average rating of "Moderate Buy" and a consensus target price of $595.95.
• Intuitive Surgical reported a stronger-than-expected quarterly earnings with $2.19 EPS, surpassing estimates by $0.26, reflecting a 21.4% increase in revenue year-over-year.

Advyzon Investment Management LLC purchased a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,134 shares of the medical equipment provider's stock, valued at approximately $561,000.

Several other large investors have also bought and sold shares of ISRG. Chilton Capital Management LLC grew its holdings in shares of Intuitive Surgical by 614.3% in the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 43 shares in the last quarter. Parvin Asset Management LLC purchased a new stake in Intuitive Surgical during the fourth quarter valued at about $26,000. Global Financial Private Client LLC lifted its stake in Intuitive Surgical by 253.3% in the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 38 shares during the last quarter. Elite Financial Inc. bought a new stake in Intuitive Surgical during the 1st quarter valued at $26,000. Finally, LFA Lugano Financial Advisors SA purchased a new stake in Intuitive Surgical in the first quarter worth $30,000. 83.64% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of Intuitive Surgical stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the sale, the executive vice president directly owned 353 shares in the company, valued at $173,845.44. This trade represents a 92.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mark Brosius sold 216 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the transaction, the senior vice president directly owned 907 shares of the company's stock, valued at $510,740.77. The trade was a 19.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,903 shares of company stock valued at $7,932,778 over the last quarter. 0.70% of the stock is owned by insiders.

Intuitive Surgical Stock Down 0.6%

Shares of NASDAQ ISRG traded down $2.94 during trading on Wednesday, hitting $474.06. The company had a trading volume of 2,189,756 shares, compared to its average volume of 2,261,750. The firm has a market capitalization of $169.94 billion, a price-to-earnings ratio of 66.12, a price-to-earnings-growth ratio of 5.00 and a beta of 1.59. The stock has a fifty day simple moving average of $521.43 and a two-hundred day simple moving average of $531.52. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The business's revenue was up 21.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.78 earnings per share. On average, analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ISRG. Deutsche Bank Aktiengesellschaft downgraded shares of Intuitive Surgical from a "hold" rating to a "sell" rating and reduced their price target for the company from $515.00 to $440.00 in a research report on Monday, June 9th. Wall Street Zen raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Wells Fargo & Company increased their price target on shares of Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a report on Wednesday, July 23rd. Robert W. Baird reduced their target price on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Finally, BTIG Research lifted their price objective on shares of Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $595.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.